JCAR015 in ALL: A Root-Cause Investigation.
After conducting an internal probe of the five deaths that halted JCAR015's development for acute lymphoblastic leukemia, Juno Therapeutics has concluded that multiple factors were at play. A surge in inflammatory cytokine levels from rapid, early T-cell proliferation may have provoked the blood-brain barrier disruption seen in these patients, inducing fatal cerebral edema.